Microbiological contamination of products and processes in a lab and manufacturing environment continues to be a major problem to the Pharmaceutical and Biotechnological industries and its regulators. The potential impact of such contamination can be enormous, and does not only create health and safety problems but can also cost companies millions in lost product revenue.

Regulators will endeavour to ensure that the safety of the health care consumer is never compromised. Aseptic processing attracts a high level of regulatory scrutiny due to the risks associated with this type of manufacturing and its potential adverse effect on the health care consumer

SMi’s Pharmaceutical Microbiology conference will aim to provide an expert and highly accredited speaker line up including 13 pharma speakers who will focus on the latest developments and procedures used in the identification and prevention of contaminating agents, updates on new rules and regulations and the challenges facing the Pharmaceutical Microbiology industry. Attending will enable you to:

• Discuss developments in tools, techniques and procedures used in identification and control of contaminants

• Evaluate the handling of traditional drug and biologics & sterile product manufacturing

• Hear about design, construction and validation of sterile facilities and equipment

• Engage with those currently working on producing the rapid microbial methods

For more information visit www.smi-online.co.uk/goto/pharma-microbiology16.asp alternatively contact Annie Blundell on +44 0 207 827 6090 or email on abundell@smi-online.co.uk

The SMi Group is a world leader in business to business information. With nearly two decades in the business, thousands of senior executives from blue chip companies have already benefitted from SMi’s highly targeted conferences, workshops and publications. For more information visit www.smi-online.co.uk

SMi Group Ltd
2nd Floor South, Harling House
47-51 Great Suffolk Street,
London, SE1 0BS

This release was published on openPR.